adoptive immunotherapy

Phase 2Cell therapy

MM.D. Anderson Cancer Center

adoptive immunotherapy is one of 121 biologic programs targeting Metastatic Melanoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

120

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic MelanomaActive, not recruiting

Cytomegalovirus InfectionActive, not recruiting

Hepatocellular CarcinomaActive, not recruiting

PsoriasisActive, not recruiting

Metastatic MelanomaPhase 1

Active, not recruiting

Cytomegalovirus InfectionPhase 2

Active, not recruiting

Hepatocellular CarcinomaPhase 2/Phase 3

Active, not recruiting

PsoriasisPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

797 competitors in Hepatocellular Carcinoma

#DrugCompanyPhaseTrials

adoptive immunotherapy

MM.D. Anderson Cancer Center

Phase 2

1 2

Viread

Gilead

Preclinical

1 3

Doptelet

AAkarx

Preclinical

1 4

Miraclid

TTechpool Bio-Pharma Co., Ltd.

Preclinical

1 5

Statin

Bristol-Myers Squibb

Preclinical

1 6

Lyrica

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

—7

Anlotinib

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Preclinical

5 8

QL1706

Qilu Pharmaceutical Co., Ltd.

Preclinical

5 9

Anti-PD-1 Monoclonal Antibody

IiTeos Therapeutics

Preclinical

3 10

Immune Checkpoint Inhibitor

IImmuneSensor Therapeutics Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cytomegalovirus Infection1 trial

T-Lymphocyte Infusion or Standard Therapy in Treating Patients at Risk of Cytomegalovirus Infection After a Donor Stem Cell Transplant

Unknown status·UUniversity Hospital Birmingham·Phase 2·NCT00986557·78 enrolled

Psoriasis1 trial

Autologous Cytokine Induced Killer Cells (CIK) for Patients With Severe Psoriasis

Completed·—·Phase 1/2·NCT01894373·10 enrolled

Gastrointestinal Tumors1 trial

CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors

Terminated·MM.D. Anderson Cancer Center·Phase 1·NCT02757391·1 enrolled

Metastatic Melanoma1 trial

Cyclophosphamide and Fludarabine Followed by Cellular Adoptive Immunotherapy and Vaccine Therapy in Patients With Metastatic Melanoma

Completed·PProf. Serge Leyvraz·Phase 1·NCT00324623·8 enrolled

Hepatocellular Carcinoma1 trial

Combination Therapy of Microwave Ablation and Cellular Immunotherapy for Hepatocellular Carcinoma

Completed·—·Phase 2/3·NCT02851784·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for adoptive immunotherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — adoptive immunotherapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for adoptive immunotherapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — M.D. Anderson Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 2[1]
Company: MM.D. Anderson Cancer Center

adoptive immunotherapy

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cytomegalovirus Infection1 trial

Psoriasis1 trial

Gastrointestinal Tumors1 trial

Metastatic Melanoma1 trial

Hepatocellular Carcinoma1 trial

References

Drug Info

Quick Facts

Related News